Home / Resources / Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

インフォグラフィック
研究開発支援サービス
Infographic Banner for Pharma R&D Annual Review 2024 Supplement NAS Infograpic

Last year was pharma’s second-hottest ever in terms of new active substances (NASs) introduced. While the forecast for NAS launches is generally fair, there are a few clouds on the horizon.

View related products
Getting the full drug RandD landscape
Pharmaprojects
世界的な医薬品研究開発の状況を追跡し、分析するための業界標準
Surfacing insights for a successful clinical trial
Trialtrove
臨床試験の戦略、設計、実施のための頼りになる情報リソース
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析

Related resources

Citeline subscribers accessing the 2023 Deal-Making Roundup white paper reported by Biomedtracker.
MAR 28, 2024
ホワイトペーパー
商業化支援サービス

2023 Deal-making Roundup

An overview of alliance, M&A, and financing deal activity across the
worldwide biopharma, medical device, and in vitro diagnostics
industries in 2023

''
研究開発支援サービス

Pharma R&D Annual Review 2024

For over 30 years, the Pharma R&D Annual Review has tracked how the climate is shifting. Browse our resources to help you navigate the climate.

Ingredients for a Deal-Rich Year Infographic banner
APR 23, 2024
インフォグラフィック
研究開発支援サービス

Ingredients for a Deal-rich Year

The global biopharma industry is poised for a deal-rich year, thanks to a variety of factors, including growing momentum in bolt-on M&A activity.

View All Resources